The prevalence of idiopathic pulmonary fibrosis has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of idiopathic pulmonary
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it signed a service agreement with The Jikei University in Japan. Under the agreement